C12orf29 Inhibitors
C12orf29 inhibitors encompass a range of compounds that can indirectly lead to the suppression of C12orf29 activity by targeting specific signaling pathways known to regulate cell growth, proliferation, and survival. The PI3K/AKT pathway is one such critical signaling cascade that, when inhibited, can result in reduced activity of many downstream proteins. Compounds like LY294002 and Wortmannin act on this pathway by directly binding to and inhibiting PI3K, which prevents the phosphorylation and activation of AKT. Downstream signaling, the absence of which could impede the function of C12orf29 if it is a downstream effector. Similarly, the inhibition of mTOR by compounds such as Rapamycin, KU-0063794, PP242, and AZD8055 has a profound effect on cellular growth signals. By disrupting mTORC1 and mTORC2, these inhibitors can lead to a decrease in protein synthesis and other anabolic processes, potentially diminishing C12orf29 activity if it is a part of the mTOR signaling network.
In addition to these pathways, the MAPK/ERK pathway is another crucial route that, when inhibited, could lead to decreased C12orf29 function. Compounds such as U0126, PD98059, PD0325901, and SL327 are particularly potent in this regard, as they selectively inhibit MEK, the kinase responsible for the activation of ERK. This inhibition prevents the phosphorylation cascade that typically follows mitogenic stimuli, which could attenuate the activity of C12orf29 if it operates downstream of or is regulated by the MAPK/ERK pathway. The stress-activated signaling pathways that respond to cellular stressors also play a role in modulating the activity of various proteins. Inhibitors like SB203580 and SP600125 target key kinases within these pathways, namely p38 MAP kinase and JNK. By inhibiting these kinases, the compounds could disrupt the response to stress stimuli and, subsequently, decrease C12orf29 activity if it is implicated in these stress response pathways.
SEE ALSO...
| Product Name | CAS # | Catalog # | QUANTITY | Price | Citations | RATING |
|---|---|---|---|---|---|---|
LY 294002 | 154447-36-6 | sc-201426 sc-201426A | 5 mg 25 mg | $121.00 $392.00 | 148 | |
A specific inhibitor of phosphoinositide 3-kinases (PI3K). LY294002 binds to the ATP-binding site of PI3K, preventing its activation and subsequent phosphorylation of AKT. Inhibition of the PI3K/AKT pathway by LY294002 can suppress downstream signaling that may be necessary for C12orf29 activity, particularly if C12orf29 is downstream of PI3K/AKT signaling. | ||||||
Wortmannin | 19545-26-7 | sc-3505 sc-3505A sc-3505B | 1 mg 5 mg 20 mg | $66.00 $219.00 $417.00 | 97 | |
An irreversible inhibitor of PI3K. Wortmannin covalently binds to the p110 subunit of PI3K, which inhibits the formation of PIP3 and blocks PI3K-dependent AKT activation. This would lead to a reduction in C12orf29 activity if its function is regulated by PI3K/AKT pathway activation. | ||||||
PD 98059 | 167869-21-8 | sc-3532 sc-3532A | 1 mg 5 mg | $39.00 $90.00 | 212 | |
A synthetic compound that specifically inhibits MEK1 activation and the subsequent activation of ERK. PD98059 blocks the phosphorylation of MEK, which can indirectly lead to decreased activation of C12orf29 if it is a downstream target of the ERK signaling pathway. | ||||||
SB 203580 | 152121-47-6 | sc-3533 sc-3533A | 1 mg 5 mg | $88.00 $342.00 | 284 | |
A pyridinyl imidazole compound that selectively inhibits p38 MAP kinase. By inhibiting p38 MAP kinase, SB203580 disrupts the cellular response to stress stimuli that may be critical for C12orf29 function, potentially leading to a decrease in its activity. | ||||||
SP600125 | 129-56-6 | sc-200635 sc-200635A | 10 mg 50 mg | $40.00 $150.00 | 257 | |
An anthrapyrazolone inhibitor that selectively inhibits c-Jun N-terminal kinase (JNK). Inhibition of JNK by SP600125 could reduce the activity of transcription factors regulated by JNK, potentially affecting C12orf29 activity if it is part of JNK-dependent signaling. | ||||||
Rapamycin | 53123-88-9 | sc-3504 sc-3504A sc-3504B | 1 mg 5 mg 25 mg | $62.00 $155.00 $320.00 | 233 | |
An mTOR inhibitor that forms a complex with FKBP12 and binds to mTOR Complex 1 (mTORC1), inhibiting its kinase activity. This leads to a decrease in cellular proliferation and growth signals that could affect C12orf29 activity if C12orf29 function is linked to mTOR signaling. | ||||||
KU 0063794 | 938440-64-3 | sc-361219 | 10 mg | $209.00 | ||
A highly specific inhibitor of mTOR that inhibits both mTORC1 and mTORC2 complexes. By inhibiting mTOR activity, KU-0063794 can reduce protein synthesis and cell growth, which could lead to a decrease in C12orf29 activity if it is involved in mTOR-regulated pathways. | ||||||
PP242 | 1092351-67-1 | sc-301606A sc-301606 | 1 mg 5 mg | $56.00 $169.00 | 8 | |
A selective ATP-competitive inhibitor of mTOR that affects both mTORC1 and mTORC2. PP242 can lead to downregulation of the mTOR signaling pathway, potentially decreasing C12orf29 activity by affecting the pathways that regulate its function. | ||||||
AZD8055 | 1009298-09-2 | sc-364424 sc-364424A | 10 mg 50 mg | $160.00 $345.00 | 12 | |
A potent and selective inhibitor of mTOR kinase, which impacts both mTORC1 and mTORC2 signaling. By inhibiting these complexes, AZD8055 can suppress the growth and survival signaling that may regulate C12orf29 activity. | ||||||
SL-327 | 305350-87-2 | sc-200685 sc-200685A | 1 mg 10 mg | $107.00 $332.00 | 7 | |
A selective inhibitor of MEK, which prevents the activation of ERK1/2. SL327 might decrease C12orf29 activity by inhibiting the MEK/ERK signaling cascade that could be upstream of C12orf29 regulatory mechanisms. | ||||||